N-Acetyl-Selank-Amidate Acetate is a highly modified, synthetic heptapeptide derivative of the naturally occurring immunomodulatory peptide tuftsin. Designed specifically for advanced preclinical investigations, this compound features dual terminal modifications—N-terminal acetylation and C-terminal amidation—to increase metabolic resistance against enzymatic degradation in laboratory research models.
N-Acetyl-Selank-Amidate Acetate is a highly modified, synthetic heptapeptide derivative of the naturally occurring immunomodulatory peptide tuftsin. Designed specifically for advanced preclinical investigations, this compound features dual terminal modifications—N-terminal acetylation and C-terminal amidation—to increase metabolic resistance against enzymatic degradation in laboratory research models.
N-Acetyl-Selank-Amidate Acetate is a synthetic, modified heptapeptide derived from the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). By incorporating an N-terminal acetyl group and a C-terminal amide group alongside the sequence extension Thr-Lys-Pro-Arg-Pro-Gly-Pro, this compound exhibits significantly enhanced enzymatic stability compared to unmodified baseline peptides in preclinical laboratory models.
In laboratory settings, researchers investigate n-acetyl-selank-amidate acetate for its unique bioactivity across central nervous system (CNS) and immunological targets. The addition of the acetate counterion yields a stable salt form optimized for aqueous reconstitution and precise concentration modeling in in vitro assays and animal models.
As a primary focus within neuropeptide research, this molecule allows investigators to study how specific structural protection strategies alter the pharmacokinetics and half-life of regulatory peptides without altering their target receptor affinities. PX1 Research supplies this compound strictly for laboratory research use only.
The baseline sequence of Selank consists of the tetrapeptide tuftsin extended at the C-terminus by the tripeptide Pro-Gly-Pro, yielding the heptapeptide sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. While effective in short-term assays, native peptide sequences remain vulnerable to rapid degradation by endogenous peptidases, including aminopeptidases and carboxypeptidases.
To mitigate rapid cleavage in cell culture media and ex vivo tissue assays, chemical modifications are introduced at both termini. N-terminal acetylation blocks aminopeptidase recognition by capping the free alpha-amine group. Concurrently, C-terminal amidation converts the terminal carboxyl group into an amide moiety, providing robust resistance against carboxypeptidase cleavage.
These combined modifications yield N-Acetyl-Selank-Amidate Acetate. Preclinical literature indicates that dual-capped analogs demonstrate significantly prolonged structural integrity in plasma and tissue homogenates. Researchers interested in exploring the complete catalog of modified neuropeptides can review our expanded collection of all peptides for comparative biochemical evaluation.
Tuftsin is a naturally occurring tetrapeptide sequence (Thr-Lys-Pro-Arg) located within the Fc domain of the heavy chain of human immunoglobulin G (IgG). It is physiologically cleaved by enzymatic processing to exert regulatory immunomodulatory functions, primarily modulating phagocytic cell activity, macrophage migration, and cytokine secretion.
Molecular modifications of the tuftsin core led to the synthesis of Selank, which appended a Pro-Gly-Pro motif to stabilize the peptide chain and introduce central nervous system regulatory activity. The further evolution into N-Acetyl-Selank-Amidate Acetate represents a second-generation optimization designed to maximize bio-availability in complex biochemical matrices.
In vitro data indicate that while the core functional sequence retains its binding affinity for target receptors, the structural modifications prevent non-specific degradation. This structural persistence allows researchers to study long-term cell signaling pathways without requiring continuous, high-frequency dosing in experimental protocols. Further documentation on regulatory sequences can be found in our dedicated research library.
Preclinical studies suggest that N-Acetyl-Selank-Amidate Acetate interacts directly and indirectly with the gamma-aminobutyric acid (GABA) system. In rodent models, exposure to Selank analogs altered the expression of genes encoding various subunits of the GABA-A receptor, particularly during conditions of induced metabolic stress.
Rather than acting as a direct GABA-A receptor agonist, experimental evidence points toward an allosteric modulatory role. Radio-ligand binding assays demonstrate that the peptide can alter receptor affinity for endogenous ligands without blocking the primary binding pocket. This subtle modulatory action leads to changes in chloride channel conductance in cultured neuronal populations.
Furthermore, researchers have observed changes in neurochemical balance, including altered expression patterns of neuroreceptor mRNA in hippocampal and cortical brain slices. These mechanisms make the compound a valuable tool for investigating non-sedating neurochemical modulation in neurobiological assays.
In addition to its GABAergic effects, N-Acetyl-Selank-Amidate Acetate influences monoaminergic signaling pathways, particularly serotonergic transmission. In vivo rodent assays indicate that administration of modified Selank analogs alters serotonin (5-HT) metabolism and its primary metabolite, 5-hydroxyindoleacetic acid (5-HIAA), within the prefrontal cortex and hippocampus.
Preclinical models also demonstrate a notable impact on the expression of Brain-Derived Neurotrophic Factor (BDNF). BDNF is a key neurotrophin involved in synaptic plasticity, neuronal survival, and dendritic arborization. When introduced to neuronal culture media or evaluated in animal models, N-Acetyl-Selank-Amidate Acetate has been shown to upregulate BDNF mRNA and protein expression.
This dual action—modulating monoamine turnover while simultaneously supporting neurotrophic gene expression—provides a compelling framework for neurodegenerative and neuroplasticity studies. Researchers conducting high-throughput screening can establish bulk account privileges through our wholesale program to ensure batch continuity across large study cohorts.
Retaining its functional heritage from tuftsin, N-Acetyl-Selank-Amidate Acetate exerts measurable effects on the immune system. In vitro macrophage and splenocyte cultures show altered expression of both pro-inflammatory and anti-inflammatory cytokines following exposure to the peptide.
Specifically, experimental data highlight changes in the transcription of Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Tumor Necrosis Factor-alpha (TNF-a). The peptide appears to exert a balancing effect, suppressing excessive pro-inflammatory cytokine expression under lipopolysaccharide (LPS) challenge while preserving basal immune competence.
This dual neuro-immune regulatory capacity makes the compound an attractive candidate for investigating the neuroimmune axis. Researchers utilize it to model how peripheral immune signals communicate with central nervous system pathways across the blood-brain barrier.
When designing neuropeptide research protocols, investigators frequently compare modified compounds against their unmodified parent structures and related regulatory peptides. Understanding these distinctions is critical for selecting the appropriate analog for specific cellular or animal assays.
Compared to baseline Selank, the N-acetylated and C-amidated variant exhibits significantly greater resistance to enzymatic cleavage in serum assays. While unmodified Selank displays a rapid initial half-life due to cleavage by endogenous peptidases, N-Acetyl-Selank-Amidate Acetate maintains structural integrity for extended periods. Similarly, when evaluating ACTH-derived regulatory peptides such as Semax and its modified derivative N-Acetyl-Semax-Amidate Acetate, researchers observe parallel enhancements in metabolic stability, although the ACTH-based analogs primarily target melanocortin and neurotrophic systems rather than GABAergic pathways.
The table below outlines the primary biochemical differences across these related research compounds:
N-Acetyl-Selank-Amidate Acetate is supplied as a lyophilized (freeze-dried) powder in sealed glass vials. To maintain peptide stability and prevent premature degradation, precise handling protocols must be observed by laboratory personnel.
Lyophilized peptide vials should be stored at -20°C upon receipt for short-to-medium term storage, or at -80°C for long-term storage. Vials should be brought to room temperature in a desiccator prior to opening to prevent condensation from forming on the lyophilized cake.
For reconstitution, use sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4) depending on the requirements of the downstream assay. Gently swirl the vial to dissolve the powder; never vortex vigorously, as mechanical shear forces can cause peptide denaturation or aggregation. Once reconstituted, aliquot the solution into single-use working volumes and store at -20°C or -80°C to avoid repeated freeze-thaw cycles.
Reliable research outcomes require absolute peptide purity and rigorous batch-to-batch consistency. PX1 Research subjects every lot of N-Acetyl-Selank-Amidate Acetate to comprehensive analytical verification in ISO 17025 accredited, third-party laboratories.
Purity is verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a chemical purity profile exceeding 98.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the precise molecular weight and sequence identity against calculated theoretical values.
Additionally, every lot undergoes Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below <0.01 EU/mg, minimizing the risk of confounding inflammatory artifacts in cell culture and animal models. Every order includes a lot-specific Certificate of Analysis (COA) documenting HPLC chromatograms and mass spectral data.
PX1 Research is an established USA-based manufacturer and supplier of reference-grade research peptides. Operating out of state-of-the-art facilities compliant with GMP principles, PX1 ensures that researchers receive clean, precise, and fully documented compounds.
Orders placed before cutoff times ship same-day from our dual dispatch hubs in California and Arizona, minimizing transit times and thermal exposure during transit. Our dedicated support staff assists university laboratories, biotechnology firms, and institutional research facilities with custom documentation and bulk procurement requirements.
To explore our full inventory of neuropeptide research standards or to review technical documentation for your upcoming experimental designs, visit our research library or contact our technical support team directly.
What is N-Acetyl-Selank-Amidate Acetate?
N-Acetyl-Selank-Amidate Acetate is a synthetic heptapeptide derived from tuftsin with added N-terminal acetyl and C-terminal amide modifications. It is designed for laboratory research investigating GABAergic, monoaminergic, and neuroimmune signaling.
How do N-acetyl and C-amidate modifications alter peptide behavior?
These terminal capping modifications protect the peptide sequence against cleavage by aminopeptidases and carboxypeptidases in biological matrices, resulting in increased metabolic stability and a prolonged half-life in laboratory assays.
What is the role of the acetate salt form?
The acetate counterion provides optimal solubility and stability for lyophilized peptide formulations, facilitating rapid reconstitution in standard laboratory buffers such as sterile water or PBS.
What are the recommended storage conditions for lyophilized powder?
Lyophilized N-Acetyl-Selank-Amidate Acetate should be stored at -20°C or -80°C in a dry environment protected from light. Vials should be equilibrated to room temperature before opening to prevent moisture condensation.
How should reconstituted peptide solutions be stored?
After reconstitution with sterile buffer, the liquid solution should be divided into single-use aliquots and stored at -20°C or -80°C. Avoid repeated freeze-thaw cycles, which can cause chemical degradation or aggregation.
What analytical tests are provided with PX1 Research peptides?
Every lot is verified by independent third-party laboratories using RP-HPLC for purity (>98%), ESI-MS for exact mass identity, and LAL assays for endotoxin quantification (<0.01 EU/mg). A lot-specific Certificate of Analysis is provided.
Can N-Acetyl-Selank-Amidate Acetate be used in cell culture assays?
Yes. Because PX1 Research products undergo strict endotoxin testing (<0.01 EU/mg), they are suitable for sensitive in vitro cell culture and immunological models without risk of endotoxin-induced cell toxicity.
How does N-Acetyl-Selank-Amidate Acetate differ from N-Acetyl-Semax-Amidate Acetate?
While both share identical chemical terminal modifications to resist enzymatic degradation, N-Acetyl-Selank-Amidate is derived from the tuftsin/GABAergic pathway sequence, whereas N-Acetyl-Semax-Amidate is derived from the ACTH fragment (4-10) targeting melanocortin receptors.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.